Enrichment Map Profiling of the Cancer Invasion Front Suggests Regulation of Colorectal Cancer Progression by the Bone Morphogenetic Protein Antagonist, Gremlin-1
Overview
Oncology
Affiliations
The cancer invasion front (CIF), a spatially-recognized area due to the frequent presence of peritumoral desmoplastic reaction, represents a cancer site where many hallmarks of cancer metastasis occur. It is now strongly suggested that the desmoplastic microenvironment holds crucial information for determining tumor development and progression. Despite extensive research on tumor-host cell interactions at CIFs, the exact paracrine molecular network that is hardwired into the proteome of the stromal and cancer subpopulations remains partially understood. Here, we interrogated the signaling pathways and the molecular functional signatures across the proteome of a desmoplastic coculture model system of colorectal cancer progression. We discovered a group of bone morphogenetic protein (BMP) antagonists that coordinates major biological programs in CIFs, including cell proliferation, invasion, migration and differentiation processes. Using a mathematical model of cancer cell progression, coupled to in vitro cell migration assays, we demonstrated that the prominent BMP antagonist gremlin-1 (GREM1) may trigger motility of cancer cell cohorts. Our data collectively demonstrate that the desmoplastic CIFs deploy a microenvironmental signature, based on BMP antagonism, in order to regulate the motogenic fates of cancer cell cohorts invading the adjacent stroma.
A comprehensive prognostic and immunological implications of Gremlin 1 in lung adenocarcinoma.
Li H, Zhou Y, Xiao J, Liu F Front Immunol. 2025; 16:1529195.
PMID: 40066442 PMC: 11891240. DOI: 10.3389/fimmu.2025.1529195.
Ginsenosides: an immunomodulator for the treatment of colorectal cancer.
Qian J, Jiang Y, Hu H Front Pharmacol. 2024; 15:1408993.
PMID: 38939839 PMC: 11208871. DOI: 10.3389/fphar.2024.1408993.
Zhang Z, Liu S, Wang Z, Wang S, Jiang L, Wang X Cancer Cell Int. 2024; 24(1):103.
PMID: 38462626 PMC: 10926681. DOI: 10.1186/s12935-024-03274-9.
Cheng S, Chiou H, Wang J, Lin M Cancers (Basel). 2023; 15(9).
PMID: 37173977 PMC: 10177044. DOI: 10.3390/cancers15092513.
Regulation of Molecular Targets in Osteosarcoma Treatment.
Celik B, Cicek K, Leal A, Tomatsu S Int J Mol Sci. 2022; 23(20).
PMID: 36293439 PMC: 9604206. DOI: 10.3390/ijms232012583.